Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Revenue (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Revenue for 17 consecutive years, with $209.8 million as the latest value for Q4 2025.

  • Quarterly Revenue changed 0.38% to $209.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $824.5 million through Dec 2025, down 1.56% year-over-year, with the annual reading at $824.5 million for FY2025, 1.56% down from the prior year.
  • Revenue for Q4 2025 was $209.8 million at Myriad Genetics, up from $205.7 million in the prior quarter.
  • The five-year high for Revenue was $213.3 million in Q3 2024, with the low at $156.4 million in Q3 2022.
  • Average Revenue over 5 years is $189.2 million, with a median of $190.6 million recorded in 2021.
  • Peak annual rise in Revenue hit 103.22% in 2021, while the deepest fall reached 46.36% in 2021.
  • Over 5 years, Revenue stood at $160.8 million in 2021, then grew by 10.57% to $177.8 million in 2022, then grew by 10.57% to $196.6 million in 2023, then rose by 7.12% to $210.6 million in 2024, then decreased by 0.38% to $209.8 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $209.8 million, $205.7 million, and $213.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.